{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "INBX",
  "name": "Inhibrx Biosciences, Inc.",
  "url": "https://orbyd.app/dossiers/INBX/",
  "json_url": "https://orbyd.app/dossiers/INBX.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Dilution overhang answered with debt: the 2026-07-16 Oxford amendment lifted the facility to $500.0M and funded $100.0M immediately, leaving the ~14.67M share count intact but the balance sheet levered into a nine-month wait for the 2027-04-14 PDUFA. At $88.66 (2026-08-07) the name sits mid-base with no docketed catalyst before an unannounced August Q2 print.",
  "invalidation_trigger": "A weekly close below $78 breaks the April–June consolidation floor and opens the gap toward the ~$60 pre-spike shelf; secondarily an equity/ATM raise priced more than 15% under market, or the HexAgon Phase 3 start and CRC FDA meeting both passing undelivered through Q4 2026.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "binary-catalyst-biotech",
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Thin float: roughly 14.67M shares outstanding with beta 3.32 - 10-30% daily ranges are normal and single headlines can gap the stock.",
    "Capital structure is debt-heavy: $275.0M drawn on the Oxford facility after the 2026-07-16 Term C funding; the $225.0M Term D is at lender discretion, not committed capital.",
    "Sell-side coverage is roughly three analysts; published targets were set after spring 2026 data and have not been re-marked to the current tape.",
    "The defining regulatory decision is the 2027-04-14 PDUFA goal date for ozekibart in conventional chondrosarcoma; everything before it is interim.",
    "Interim milestones (HexAgon Phase 3 start, CRC FDA meeting, HNSCC PFS readout) are company-guided cadence, not clock-driven regulatory dates, and can slip."
  ],
  "body_markdown": "## Current Thesis\nThe only dated corporate event since the 2026-07-12 update is financing. On 2026-07-16 Inhibrx amended its Oxford Finance loan agreement: total facility raised to $500.0M, a $100.0M Term C tranche funded immediately on top of $175.0M already borrowed, up to $225.0M of Term D available at the lenders' discretion, and warrants on 21,457 common shares issued at a $93.21 strike, immediately exercisable over ten years. The overhang flagged through the spring — that a name up several hundred percent off its low with under 15M shares outstanding would sell equity — was answered with debt instead. That keeps the share count intact and levers the balance sheet into a nine-month wait for the 2027-04-14 PDUFA on ozekibart in conventional chondrosarcoma. The tape reflects the vacuum: $88.66 close on 2026-08-07, 37.5% below the $141.84 52-week high, -34.0% over three months, RSI(14) at 58.\n\n## Bull Case\n- **Filing gate cleared and still clean.** FDA accepted the ozekibart BLA on 2026-06-15 with no filing review issues identified; PDUFA goal date 2027-04-14. Approval would make it the first systemic therapy for unresectable/metastatic conventional chondrosarcoma. Fast Track (Jan 2021) and Orphan Drug (Nov 2021) are already in hand.\n- **The registrational dataset underpinning that filing is unambiguous.** ChonDRAgon, n=206: stratified HR 0.479, median PFS 5.52 months versus 2.66 for placebo.\n- **Funded without touching the equity.** The 2026-07-16 amendment put $100.0M of cash in the door and a $500.0M ceiling behind the two lead programs; the equity component of that deal is 21,457 warrant shares against roughly 14.67M shares outstanding.\n- **Colorectal remains the fat-tail option.** Ozekibart plus FOLFIRI in heavily pretreated mCRC: 20% ORR (n=45 evaluable), median PFS 5.5 months, 87% disease control (2026-04-21) against a 1–6% historical response benchmark. An FDA meeting on a registrational design is guided to H2 2026.\n- **Second asset has a Phase 3 in front of it.** INBRX-106 plus pembrolizumab in 1L PD-L1+ HNSCC produced 44.0% confirmed ORR versus 21.4% for pembrolizumab monotherapy (n=53 evaluable, 3 CRs vs 0), disclosed 2026-05-11; HexAgon Phase 3 initiation guided Q3 2026, PFS readout Q4 2026.\n\n## Bear Case\n- **The defining event is three quarters out and nothing is docketed before it.** Acceptance on 2026-06-15 lifted the stock toward ~$95; the seven weeks since have produced one press release (the 2026-07-16 financing) and a $88.66 close on 2026-08-07.\n- **Leverage replaced dilution, it did not remove the funding question.** $275.0M is now drawn after Term C, against $161.7M cash at 2026-03-31 and a stockholders' deficit of -$21.0M; the earlier $75M draw carried a ~17.5% effective cost. Term D's $225.0M is at lender discretion — an option the lenders hold, not committed capital the company controls.\n- **The name has distributed into its own good news twice.** It fell on the 2026-05-11 HNSCC beat with an intraday trough near -30%, round-tripped the $59.88 → $155.29 spike, and slid from $116.16 (2026-05-15) to $87.01 (2026-06-05).\n- **Published targets are stale-high on thin coverage.** Roughly three analysts, targets clustered ~$150–277 with Stifel at $325 in mid-May, set after the spring data and unmarked against an $88.66 tape.\n- **Every interim item is company cadence.** HexAgon start (Q3 2026), CRC FDA meeting (H2 2026), HNSCC PFS (Q4 2026) — none carry a regulatory clock, all can slip and extend the silence.\n\n## Setup & Price Structure\n- **Life-cycle: MATURING.** The clinical narrative is known and de-risked at the filing gate (2026-06-15), but new participation is moderating — the last price-moving headline is dated 2026-07-16, and the tape has been confined roughly between the 2026-06-05 close of $87.01 and the post-acceptance ~$95 area since mid-June. Structure is intact; the flow is not expanding.\n- **Position within the range.** $88.66 on 2026-08-07 is 37.5% under the $141.84 52-week high with a -34.0% three-month return, yet RSI(14) reads 58. A mid-50s RSI on a stock down a third in a quarter describes a recovery off a lower low that has stalled mid-range, with no extension above a rising trend to chase.\n- **The shelf that matters.** The April–June consolidation floor sits in the $78–$87 band. Below it the prior spike left an air pocket down toward the ~$60 pre-spike shelf, with no intervening structure built on volume.\n- **Crowding and positioning observables.** Sell-side targets sit far above spot on roughly three-analyst coverage. The lender struck ten-year warrants at $93.21 — an externally set reference above the 2026-08-07 close and near the June–July range top. Float is roughly 14.67M shares with beta 3.32, so 10–30% daily candles occur on ordinary news. No equity offering has been announced, and as of 2026-08-08 no Q2 earnings date had been released.\n\n## Catalyst Calendar (next 30 days)\n\n- **~Q3 2026 (est., undated)** — HexAgon Phase 3 initiation in 1L PD-L1+ HNSCC. The only near-term item capable of restarting flow.\n- **H2 2026 (est., undated)** — FDA meeting on a registrational colorectal design.\n- **No docketed regulatory date falls inside the next 30 days.** The PDUFA goal date is 2027-04-14.\n\n## Elapsed catalysts\n\n- **~mid-August 2026 (est., unannounced)** — Q2 2026 results and 10-Q. Q1 was released 2026-05-14; no date had been published as of 2026-08-08. What resolves: cash after the $100.0M Term C draw, quarterly burn, and whether management frames Term D as expected or contingent. *(passed 1d ago)*\n\n## What Would Change Our Mind\nThe base is the entire argument here — a de-risked filing, an intact share count, and a nine-month wait. Lose the base and what remains is a levered pre-commercial biotech with no dated catalyst. A weekly close below $78 breaks the April–June consolidation floor and opens the gap toward the ~$60 pre-spike shelf; that is the gradeable break. Secondary conditions that would independently change the read: an equity or ATM raise priced more than 15% under market, which would reverse the interpretation of the 2026-07-16 debt deal; the Q2 filing disclosing that Term D funding is being sought earlier than the catalyst schedule implies; or the HexAgon start and CRC FDA meeting both passing without announcement, pushing the next dated event past Q4 2026 and taking the theme to SATURATED. On the other side, a dated HexAgon first-patient-dosed release or a disclosed registrational CRC path would restore an interim clock and change the life-cycle read from moderating to expanding.\n\n## Correlation Notes\n- Beta 3.32 means index and sector drawdowns are amplified; small-cap biotech risk appetite (XBI/IBB direction) sets the drift while the name has no company-specific news.\n- The balance sheet makes it rate- and credit-sensitive in a way cash-funded peers are not: with $275.0M drawn and a ~17.5% effective rate on the earlier tranche, financing-cost headlines transmit to equity value directly.\n- On data and regulatory days the sector correlation breaks — 2026-05-11 and 2026-06-15 both produced idiosyncratic moves against whatever the sector did.\n- There is no listed pure-play comparable in conventional chondrosarcoma, so cross-read hedges are approximations; INBRX-106 links the name loosely to the PD-1 combination cohort of immuno-oncology developers.",
  "first_seen": "2026-04-23",
  "last_analyzed": "2026-08-08T16:01:18+00:00",
  "last_synthesized": "2026-08-08",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}